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C A N C E R
Comment on “PP2A inhibition sensitizes cancer stem 
cells to ABL tyrosine kinase inhibitors in BCR-ABL 
human leukemia”
Danilo Perrotti1,2*†, Anupriya Agarwal3*, Claire M. Lucas4*, Goutham Narla5*, Paolo Neviani6*, 
Maria D. Odero7*, Peter P. Ruvolo8*, Nicole M. Verrills9*
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.
When trying to identify inhibitors of Abelson helper integration site–1 
(AHI-1), a scaffold protein involved in the maintenance of Janus 
kinase 2 (JAK2)–-catenin survival signals in chronic myeloid leu-
kemia (CML), Lai et al. found that the nonspecific protein phospha-
tase 2A (PP2A) inhibitor cantharidin inhibited growth of K562 CML 
cells by 93% (1). Despite PP2A being already described as a key reg-
ulator of leukemia stem cell (LSC) and progenitor cell survival and 
proliferation in CML (2, 3), Lai and co-workers (1) claim that 
they identified PP2A as a CML LSC regulator and that, in agreement 
with LB100 clinical trial results (4), the PP2A inhibitor LB100 sensitizes 
CML LSCs/progenitors to ABL1 tyrosine kinase inhibitor (TKI)–
induced apoptosis by suppressing PP2A-B55–dependent JAK2–
AHI-1–-catenin–driven survival signals. However, given that only 
cell lines and not primary TKI-resistant normal and CML stem cells 
were examined and that LB100 is primarily a cytostatic drug that 
does not sensitize CML LSCs to TKI-mediated killing, this claim is 
speculative at best.
PP2A is a tumor suppressor inactivated in nearly all types of cancer, 
mostly by increased expression of its inhibitors SET (I2PP2A, PP2A 
inhibitor 2) and CIP2A, and preclinical studies have shown strong 
anticancer effects and very low toxicity profiles of SET-sequestering 
and PP2AA-interacting PP2A-activating drugs (PADs) (3). Con-
versely, PP2A-inhibiting drugs (PIDs; such as LB100), developed on 
the basis of the highly toxic and tumor-promoting phosphatase in-
hibitors okadaic acid and cantharidin, induced Akt activation- and 
PP2A-B55 inhibition- dependent mitotic catastrophe in tumor lines 
and reduced tumor growth but did not induce regression while caus-
ing grade 3 toxicity in patients enrolled in the first LB100 trial (4).
BCR-ABL1 inhibits PP2A activity in BCR-ABL1+ cells, including 
K562 (3); hence, tyrosine kinase inhibitors (TKIs) should antagonize 
and not synergize with PIDs’ activity. To claim that PIDs synergize 
with TKIs to inactivate PP2A and trigger apoptosis of TKI non-
responder (NR) chronic myeloid leukemia (CML) leukemia stem 
cells (LSCs) and progenitors (1), apoptosis and not cell viability 
should have been evaluated in primary healthy and CML CD34+ stem 
and progenitor cell fractions and not in cell lines. Moreover, PP2A 
activity in TKI- and TKI + LB100–treated cells must also be shown. 
In addition, vector control and PP2Ac-shRNA (short hairpin RNA) 
variants of K562-IMR cells are not suitable as genetic proof of prin-
ciple because expression of various proteins in parental compared 
to scramble-shRNA cells is not similar and is increased in scramble- or 
PP2Ac-shRNA–expressing K562-IMR cells. Moreover, a direct 
comparison of K562-IMR with K562 cells is needed to determine 
whether expression of factors such as AHI-1, -catenin, and phospho-
rylated signal transducer and activator of transcription 5 (pSTAT5) 
is also altered in drug-sensitive cells.
Thirteen studies from 11 independent groups (3) reported that 
PP2A activity is reduced up to 80% in a SET-dependent but BCR-
ABL1 kinase-independent (LSCs) and -dependent (progenitors) manner 
in TKI-sensitive and -resistant (T315I included) chronic (CP) and 
blastic crisis (BC) phase CML and that PP2A reactivation triggers 
apoptosis of nearly all CML but not healthy stem/progenitor cells 
in vitro and in animals (Fig. 1A). Notably, 15 Gene Expression 
Omnibus profiles (GDS3042/210231_x_at, GDS3042/213048_s_at, 
GDS3043/210231_x_at, GDS3043/213048_s_at, GDS3044/210231_x_
at, GDS3044/213048_s_at, GDS3045/210231_x_at, GDS3045/213048_s_
at, GDS3046/210231_x_at, GDS3046/213048_s_at, GDS3047/213048_s_at, 
GDS3047/210231_x_at, GDS3048/210231_x_at, GDS3048/213048_s_at, 
and GDS5406/213048_s_at) of untreated and TKI-treated CML cells 
showing that BCR-ABL1 induces SET expression also contradict the 
authors’ findings, and the statement that unchanged SET expression 
in K562-IMR–PP2Ac-shRNA cells contrasts with Neviani et al. (2) 
is incorrect because the latter did not show that PP2A directly inhibits 
SET. Likewise, their claim that forskolin-induced PP2A activation 
depends on adenylate cyclase/cyclic adenosine monophosphate in-
duction (3) is incorrect; in fact, Perrotti’s group demonstrated exactly 
the contrary.
PADs and PIDs have dissimilar effects in CML (Fig. 1A); thus, 
the decision on whether it is better to restore or further reduce PP2A 
activity in CML trials for patients with NR-CML-CP and CML-BC and 
for LSC eradication in patients with durable complete molecular 
remission (CMR) or deep molecular remission (MR4,5) CML rests 
on the ability of these drugs to effectively and selectively kill TKI- 
resistant quiescent LSCs (qLSCs) without inducing adverse effects. 
Notably, PID translatability into CML clinical settings remains 
speculative because LB100 and LB100 + TKI effects on normal 
hematopoiesis and quiescent leukemic and normal hematopoietic 
stem cells (HSCs) were evaluated neither in vitro nor in vivo.
Analysis of LB100/LB102 activity (1) indicates that these are pri-
marily cytostatic drugs with almost null and very modest sensitizing 
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activity toward TKI-induced CML LSC and progenitor cell apoptosis, 
respectively. In fact, LB100/LB102 induced apoptosis in only ~40% 
of cells without affecting the survival of leukemic animals (1), and 
their combination with TKIs only increased apoptosis by 0 to 10% and 
survival of leukemic animals by 0 to 30%. Colony-forming cells (CFCs) 
were decreased by 25 and 70%, and long-term culture-initiating cells 
(LTC-ICs) were decreased by 50 to 80% and 80 to 98% in CML cells 
treated with LB100/LB102 alone or combined with TKIs, respectively 
(Fig. 1B). Conversely, leukemic TKI-resistant quiescent long-term 
HSC (LT-HSC) numbers remained similar in LB100 and LB100 + 
TKI–treated animals (Fig. 1A). This likely depends on LB100- 
induced cell cycle arrest and impaired in vitro and in vivo LSC and 
progenitor proliferation and not on LB100 sensitization to TKI- 
induced apoptosis. In fact, TKI-induced K562-IMR apoptosis was 
only marginally affected by shRNA-mediated PP2Ac inhibition, 
TKI increased apoptosis of LB100-treated CML progenitors by <10% 
(Fig. 1B), and TKI activity and not LB100 sensitization reduced 
granulocyte macrophage precursors (GMPs) in LB100 + TKI–treated 
mice (Fig. 1B), and reduced CFCs/LTC-ICs and LT-HSCs in LB100- 
and LB100 + TKI–treated cells and animals.
In addition, safety concerns emerge from Lai et al. (1). LB100/
LB102 reduced CFCs of TKI-treated healthy progenitors by ~50% 
and increased leukemia-induced splenomegaly associated with ab-
errant infiltration of BCR-ABL1+ cells in the bone marrow and liver, 
indicating that PIDs may enhance leukemogenesis in TKI-resistant 
patients and induce leukopenia in TKI- 
responding CML patients. Furthermore, 
reduced leukemia infiltration and BCR-
ABL1 activity in LB100 + TKI–treated 
animals are not LB100-sensitizing effects 
but were dependent on the well-known 
TKI sensitivity of BV173 and SCL-tTA–
BCR-ABL cells.
Mechanistically, the authors indicated 
that LB100-sensitive PP2A-B55 activity 
is essential for -catenin–dependent in-
duction of cell cycle and survival regu-
lators [cyclin D1 (CCND1) and Myc] in 
LSCs and progenitors. However, they do 
not provide data indicating that PP2A-
B55 activity, but not JAK2-SET–induced 
PP2A inhibition (2), is essential for - 
catenin–dependent survival of CML qLSCs 
and proliferating progenitors. In addi-
tion, it remains unknown whether RNA 
interference– and LB100-induced PP2A-
B55 inhibition impairs proliferation and 
self-renewal and induces apoptosis of CML 
cells through inhibition of -catenin and 
CCND1 and induction of mitotic catas-
trophe without affecting normal hemato-
poiesis. Furthermore, the authors’ concept 
that LB100 activates essential BCR- 
ABL1(AHI-1)–JAK2–AKT–glycogen 
synthase kinase-3 (GSK3)–-catenin– 
mediated CML mitogenic and survival 
pathways is unrealistic because inacti-
vation of these essential CML survival 
signals requires PP2A activity (2).
Because LB100 increases AktS473/T308 and -cateninS45/T41 and 
reduces total -catenin, Lai et al. (1) suggested that LB100 decreases 
-catenin stability through inhibition of PP2A-B55– dependent 
S45/T41 dephosphorylation. However, data showing that LB100 
neither increased -cateninS45/T41 in LB100-treated (48 hours) 
K562-IMR cells nor reduced total -catenin in K562, K562-IMR, 
and untreated and LB100-treated shRNA-PP2Ac–K562-IMR cells 
argue against the existence of an LB100-sensitive PP2A-B55–-
catenin pathway. Thus, reduced -catenin expression and stability 
in TKI- and TKI + LB100–treated progenitors depend on BCR-
ABL1 activity and not PP2A inhibition. Accordingly, unchanged 
AktS473 expression in untreated and LB100- treated K562-IMR cells 
indicates that LB100 does not inactivate PP2A-B55.
Notably, reduced B55 was detected in TKI- and in LB100-treated 
and shRNA-PP2Ac–expressing K562-IMR cells. If, as stated, 
PP2A-B55–-catenin pathway is essential for CML LSC survival 
(1), then it is expected that TKI-induced PP2A-B55 inhibition 
would induce LSC mitotic arrest and -catenin inactivation and 
reduce CML qLSC numbers. Instead, CML qLSCs are TKI-resistant, 
and TKIs expand the G0 cell cycle fraction without inducing 
M phase arrest or mitotic catastrophe. This and the notions that 
B55 inhibition is a dismal prognostic factor in leukemias and 
that PP2Ac down-regulation is dispensable for TKI-induced B55 
inhibition suggest that PP2A-B55 activity is not critical for CML 
survival.
Fig. 1. Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic 
myeloid leukemia. (A) Hematopoietic stem cell (HSC) and progenitor activity after protein phosphatase 2A–activating 
drug (PAD) or protein phosphatase 2A–inhibiting drug (PID) treatment. (1) Eight PADs were independently tested in 
nine laboratories. (2) Average of data from Perrotti group’s publications. (3) PAD-induced apoptosis also in BCR-ABL1T315I 
chronic myeloid leukemia (CML). (4) PID values are from Lai et al. (1). (5) FTY720 and derivatives increase bone marrow 
(BM) homing of normal but not tumor HSCs. (B) Effects of LB100 on CML cell proliferation and survival. Data are from 
figures 6 and 8 and figure S8 of Lai et al. (1). TKI, tyrosine kinase inhibitor; CFC, colony-forming cell; LTC-IC, long-term 
culture-initiating cell; NR, nonresponder; N/A, not applicable; N.S, nonsignificant differences; wk, weeks; DAS, dasatinib; 
RT-PCR, reverse transcription polymerase chain reaction. NBM, normal bone marrow; CFSEmax, maximum staining 
with carboxyfluorescein succinimidyl ester; hLSC, human leukemia stem cell; CMPs, common myeloid progenitors; 
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The correct analysis of LB100 and LB100 + TKI effects is also 
compromised by the unexpected response of known BCR-ABL1 and 
PP2A targets to TKI and LB100 treatment, respectively. This raised a series 
of concerns. Reportedly, wild-type and mutated BCR-ABL1, JAK2, 
and Akt suppress GSK3 and PP2A activities to prevent their in-
activation and that of extracellular signal–regulated kinase (ERK), 
STAT5, SET, AHI-1, MYC, CCND2, and -catenin. If PP2A-B55 
was essential for CML, why did LB100 and/or PP2Ac down-modulation 
not affect BCR-ABL1, JAK2Y1007/8, AktS473, -catenin, and ERKY204 ex-
pression (or activity) and induce apoptosis in only 15% of cells? 
Why are the amounts of pJAK2, pAkt, and pERK unchanged in 
TKI-treated (imatinib-sensitive) K562 cells when BCR-ABL activity 
(4G10) and STAT5 phosphorylation are inhibited? Last, why did the 
expression of AHI-1 correlate with BCR-ABL expression and activity 
in previous work from the same group (5) but not in this one (1)?
In conclusion, the evidence that PIDs arrest proliferation of TKI- 
resistant CML progenitors but do not sensitize them to TKI-induced 
apoptosis (1) and that genetic PP2A inactivation or LB100 treatment 
does not affect CML leukemogenic potential (6) indicates that PP2A 
functions in CML as a tumor suppressor and that its inhibition is of 
scarce therapeutic relevance because the residual PP2A activity is 
required for cell cycle progression but dispensable for CML patho-
genesis. Moreover, the existence and therapeutic relevance of a 
JAK2–AHI-1–PP2A-B55–-catenin survival pathway in CML LSCs 
is a mere speculation at this stage.
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